In a report issued on February 21, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Eagle Pharmaceuticals Inc (EGRX), with a price target of $40. The company’s shares closed on Friday at $46.23.
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 7.7% and a 40.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Supernus Pharmaceuticals.
Eagle Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $49, implying a 6.0% upside from current levels. In a report issued on February 20, Cantor Fitzgerald also maintained a Hold rating on the stock with a $58 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $85.66 and a one-year low of $36.03. Currently, Eagle Pharmaceuticals Inc has an average volume of 206.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban; ryanodex; docetaxel injection, non-alcohol formulation; and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
